⚔️ 36: Eli Lilly vs Novo Nordisk
The Stock Battle - Round 36: $LLY vs $NVO
Every two weeks, we host a Stock Battle on our X page between two competing companies. Which one is the favorite among our followers? And find out which one we think has the stronger fundamentals.
And the winner is... Novo Nordisk with 66% of the votes!
Eli Lilly and Novo Nordisk are two major giants, in the pharmaceutical world, especially known for their weight-management products like Ozempic and Mounjaro. These drugs have become go-to treatments for both diabetes and weight loss, and both companies have benefited from their success. While they’re both in similar markets, they have different strategies and business models.
Novo Nordisk is mainly focused on diabetes care and weight management. Their drug, Ozempic, is well-known for managing type 2 diabetes and helping people lose weight. Novo Nordisk has been able to build a strong reputation in these areas, and demand for their products continues to rise. Eli Lilly, on the other hand, offers a wider range of products. Along with diabetes and weight loss treatments, Lilly is also active in oncology, immunology, and neurology, which makes it a more diversified company.
Curious which of these companies we consider the best? Find out below, exclusively available to our premium members.